Clinical Trial

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is an open-label, multicenter Phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of QLC5508 in combination with NHA (abiraterone or enzalutamide), QLC5508 in combination with QLH12016, QLC5508 in combination with QLH12016 and NHA (abiraterone or enzalutamide), and QLH12016 in combination with NHA (abiraterone or enzalutamide) in subjects with advanced prostate cancer. The study consists of two stages: Phase Ib: is the combination dose-escalation stage, during which the recommended Phase II dose (RP2D) will be determined. Phase II is the efficacy exploration stage, in which, based on the RP2D established in Phase Ib, the therapeutic efficacy will be further evaluated in the target indication.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-21.
Status change: Not Yet Recruiting → Recruiting 2026-06-01
Trial Details
NCT Number NCT07198633
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Advanced Prostate Cancer
Enrollment 212 participants
Start Date 2025-11-05
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-02